MX2022003018A - Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. - Google Patents

Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.

Info

Publication number
MX2022003018A
MX2022003018A MX2022003018A MX2022003018A MX2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A MX 2022003018 A MX2022003018 A MX 2022003018A
Authority
MX
Mexico
Prior art keywords
treating narcolepsy
tak
compound
methyl
subject
Prior art date
Application number
MX2022003018A
Other languages
English (en)
Inventor
Deborah Hartman
Rebecca Evans
Helene Faessel
Shinichiro Tanaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022003018A publication Critical patent/MX2022003018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describe un método para tratar la narcolepsia tipo 1 en un sujeto que lo necesite, que comprende administrar al sujeto una cantidad efectiva de 3-((metilsulfonil)amino)-2- (((4-fenilciclohexil)oxi)metil)piperidina-1-carboxilato de metilo (Compuesto (I)), o una sal del mismo, en donde la concentración plasmática del Compuesto (I) es de aproximadamente 5.04 ng/mL o más durante aproximadamente 1 hora o más. También se describen composiciones para tratar la narcolepsia tipo 1 que comprenden el Compuesto (I).
MX2022003018A 2019-09-13 2020-09-12 Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia. MX2022003018A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900298P 2019-09-13 2019-09-13
US202063031686P 2020-05-29 2020-05-29
PCT/IB2020/058483 WO2021048822A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Publications (1)

Publication Number Publication Date
MX2022003018A true MX2022003018A (es) 2022-06-14

Family

ID=72560858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003018A MX2022003018A (es) 2019-09-13 2020-09-12 Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.

Country Status (11)

Country Link
US (1) US20220339143A1 (es)
EP (1) EP4028004A1 (es)
JP (1) JP2022547711A (es)
KR (1) KR20220062012A (es)
CN (1) CN114980892A (es)
AU (1) AU2020346456A1 (es)
BR (1) BR112022004587A2 (es)
CA (1) CA3154321A1 (es)
CO (1) CO2022004596A2 (es)
MX (1) MX2022003018A (es)
WO (1) WO2021048822A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3215906A1 (en) * 2021-04-02 2022-10-06 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for post operation recovery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319498B1 (en) 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
US6545127B1 (en) 1999-06-28 2003-04-08 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US10188652B2 (en) * 2014-10-23 2019-01-29 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
MX2017016413A (es) * 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
PL3411358T3 (pl) * 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie

Also Published As

Publication number Publication date
WO2021048822A1 (en) 2021-03-18
US20220339143A1 (en) 2022-10-27
KR20220062012A (ko) 2022-05-13
AU2020346456A1 (en) 2022-04-14
BR112022004587A2 (pt) 2022-06-14
CA3154321A1 (en) 2021-03-18
CN114980892A (zh) 2022-08-30
EP4028004A1 (en) 2022-07-20
CO2022004596A2 (es) 2022-08-30
JP2022547711A (ja) 2022-11-15

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2021001752A (es) Compuestos de pirrolo-dipiridina.
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
BR112013020620A2 (pt) análogos de ácido 4-hidroxibutírico
PE20130151A1 (es) Sintesis estereoselectiva de activos que contienen fosforo
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
MX2008011096A (es) Composicion para el tratamiento de superficies metalicas, metodo para el tratamiento de superficies metalicas y material metalico.
BR0212652A (pt) Composição para o tratamento de uma formação subterrânea, método de tratamento de uma formação subterrânea para aumentar a permeabilidade, e método de tratamento de um conjunto de escoramento numa fratura numa formação subterrânea para aumentar a sua permeabilidade
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
EA202193015A1 (ru) Ингибиторы cdk
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
AU2020231934A8 (en) Compounds useful in HIV therapy
AU2021285747A8 (en) LPA receptor antagonists and uses thereof
MX2022003018A (es) Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2022012998A (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2 -(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-aci do ciclo-propilpropanoico y su forma cristalina para uso como principio activo farmaceutico.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
ZA202206588B (en) Metal salts and uses thereof